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In this review, we trace the concept and potential functional role of regulatory idiotypes 
in the immune response to human immunodeficiency virus type 1 (HIV-1), simian immu-
nodeficiency virus, and hepatitis C virus (HCV). A major idiotype involved in these viral 
infections is recognized and defined by a murine monoclonal antibody (1F7). Antibodies 
expressing the idiotype defined by 1F7 are dominant in HIV-1 infection and are also 
found on many broadly neutralizing antibodies against HIV-1. This regulatory idiotypic 
axis offers opportunities for exploitation in vaccine development for HIV-1, HCV, and 
other chronic viral infections.
Keywords: idiotype, 1F7, Hiv, Siv, HCv
ANTi-iDiOTYPiC ANTiBODieS AND iMMUNe ReGULATiON
Oudin and Jerne are the founders of the Idiotype Concept (1, 2). They “discovered” that one antibody 
could recognize another antibody as an individual and unique member of the immune system. The 
uniqueness of an antibody lies in the variable region of heavy and light chains and has been named 
idiotype. Essential insight into the Idiotypic network has emerged from studies on the immune 
response of mice to phosphorylcholine (PC) [for review, see Ref. (3)]. Evidence that idiotype–anti-
idiotype interactions may play a role in the regulation of the immune response came in part from 
the observation that auto-anti-idiotypic antibodies appear during an immune response to PC (4, 5). 
Similar evidence of auto-anti-idiotypic antibodies was later discovered in human immunodeficiency 
virus type 1 (HIV-1)-infected individuals who had antibodies against the 1F7 idiotype (6).
The utility of anti-idiotypic antibodies as immune regulatory molecules was initially demon-
strated by Cosenza and Kohler who showed that an anti-idiotype antibody suppressed the response 
to PC (7, 8). Eichmann and Rajewski later suggested that anti-idiotype antibodies could be used as 
vaccines (9). In the following decades, anti-idiotypic antibodies have been investigated and probed 
as therapeutic antibodies in a variety of infectious diseases and malignancies. These anti-idiotypes 
were used successfully as surrogate antigens, termed Ab2beta, internal image or network antigen, 
thus replacing the original antigens used as therapeutic vaccines (10).
Anti-idiotypic antibodies were defined as Ab2alpha, Ab2beta, and Ab2gamma, reflecting their 
biological function as therapeutic antibodies. While Ab2alphas are non-internal images, which are 
non-biologically effective antibodies, Ab2gammas are non-internal images, which are biologically 
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effective antibodies. Therefore, Ab2beta and Ab2gamma, being 
both biological effective as therapeutic antibodies, were inte-
grated under the term network antigens (11). The term “idiotype” 
is used to refer to the entire collection of unique idiotopes within 
the variable region of a monoclonal antibody (mAb), whereas the 
term “idiotope” refers to a single determinant recognized within 
the variable region of an antibody.
Idiotypes expressed on anti-pathogen antibodies might also 
be utilized as disease markers (12). In the following, we will 
review the recent progress or lack thereof in the utilization of 
anti-idiotypes as therapeutic antibodies or disease markers. We 
will focus on HIV-1 and hepatitis C virus (HCV) infection as both 
HIV-1 and HCV can lead to cancer in late stages of infectious 
disease (13, 14).
eXPReSSiON OF THe 1F7 iDiOTYPe ON 
ANTiBODieS AGAiNST iMMUNe 
DeFiCieNCY-CAUSiNG ReTROviRUSeS
Several HIV infection-related anti-idiotype studies preceded 1F7 
anti-idiotype research. These previous studies demonstrated that, 
in contrast to 1F7, some anti-idiotypes could be used as surrogate 
antigen to stimulate immune responses against HIV.
Morrow et  al. demonstrated that anti-idiotypic antisera 
against a mAb specific for a p24 gag region epitope detected a 
common interspecies idiotype associated with anti-HIV response 
(15). Kang et al. produced an anti-idiotypic mAb (3C9) related 
to gp120-affinity purified human anti-gp120 antibodies directed 
against the conserved CD4 attachment site of gp120. It was 
subsequently shown that immunization with anti-idiotype 3C9 
elicited broadly neutralizing antibodies (BnAbs) in naive, non-
HIV-infected monkeys (16).
The murine monoclonal antibody defining the 1F7 idiotype, 
and named 1F7, was originally raised against pooled human anti-
bodies against HIV-1, subcloned, and further selected by ELISA 
against specific anti-HIV-1 antibodies captured by HIV-1 pro-
teins gp120 and p24 (17). Pooled human immunoglobulin from 
non-HIV-1-infected individuals (IVIG) was used as negative 
control in the selection process. Further investigation revealed 
that human monoclonal anti-gp120, and anti-p24 antibodies, as 
well as anti-HIV-1 human serum antibodies, share the common 
idiotype/clonotype 1F7 (18).
Subsequent research identified a region (FR3–CDR3) on 
three human mAb directed against gp120 or p24 that bound 
to the murine anti-1F7 mAb, allowing production of a peptide 
mimicking the idiotypic region. Design of the peptide was 
based on the molecular recognition theory. As such, regions of 
inverse hydropathy between the variable sequence of the anti-
1F7 and the human mAb, which are assumed to be involved 
in the idiotype–anti-idiotype contacts, were selected for the 
peptide design (19). Human anti-HIV-1 serum antibodies 
from a variety of HIV-1-infected individuals bound to this 
peptide, indicating an auto-anti-idiotypic humoral immune 
response to the 1F7 idiotype (6). Further evidence of a biologi-
cal role for the 1F7 idiotype in HIV-1 infection was provided 
by studies of cellular immunity. Culture of peripheral blood 
mononuclear cells (PBMC) from HIV-1-infected individuals 
with 1F7-induced apoptosis of CD4+ and CD8+ T cells and the 
1F7 mAb selectively blocked cytotoxicity of CD8+ T cells from 
HIV-1-infected individuals (20, 21). The 1F7 idiotype is also 
expressed on antibodies against the envelope glycoprotein of 
simian immunodeficiency virus (SIV)- and chimeric simian-
human immunodeficiency virus (SHIV) in infected rhesus 
monkeys (22, 23). As such, the impact of idiotypic regulation 
through targeting the 1F7 idiotype was explored in the SHIV-
IIIB infection model (24, 25). Suppressing expression of the 
1F7 idiotype through administration of the murine 1F7 mAb 
to macaques chronically infected with SHIV-IIIB increased 
the potency and breadth of neutralizing antibodies, with an 
increase in neutralization titer against HIV-IIIB and cross-
neutralization of HIV-MN as tested by syncytium forming 
microassay (25). This was interpreted as a result of relieving 
clonal dominance of the 1F7 idiotype in the humoral response 
to SHIV, such that new antibodies could arise.
The murine 1F7 mAb has been designated as an Ab2delta 
antibody to distinguish it from Ab2alpha, Ab2beta, and 
Ab2gamma anti-idiotypes (26). Recently, we found that this 
anti-idiotypic clone also stained local SIV gp41-antibodies 
emerging in naive macaques after intravenous vaccination with 
SIVmac239 delta Nef and vaginal challenge with wild type SIV 
(27). Local antibody production in the genital tract correlated 
with the maturation of protection against high-dose pathogenic 
SIV vaginal challenge (28).
eXPReSSiON OF THe 1F7 iDiOTYPe ON 
ANTi-HCv ANTiBODieS
Since 1F7 is a widely shared idiotype/clonotype, some cross-
reactivity with antibodies directed to similar structures is not 
surprising. Parallel research revealed that the 1F7 idiotype 
is also expressed on antibodies against a number of different 
HCV proteins (29). Since approximately 20% of HCV-exposed 
individuals spontaneously clear HCV infection and chronic HCV 
infection can be cured through treatment, this finding enabled 
investigation of a possible relationship between expression levels 
of antibodies bearing the 1F7 idiotype and development or 
persistence of chronic infection (30). Direction of anti-pathogen 
immune responses along pathways with inherent limitations as 
to the potency of induced antibodies was previously suggested 
as a mechanism by which chronic pathogens may have evolved 
to subvert the immune response (29, 31, 32). For example, if the 
dominant antigens of the pathogen have some similarity to self 
antigens, then conserved aspects of immunological self-tolerance 
could limit the efficacy of responses against the pathogen (33, 
34). In the context of idiotypic regulation of the immune system, 
we have also proposed that chronic pathogens may have evolved 
to stimulate immune responses along conserved idiotypic axes 
defining areas of high network connectivity (29, 30). Stimulating 
B cells with extensive internal connectivity would propagate high 
levels of idiotypic recognition with reciprocal stimulation of 
potentially irrelevant B cell clones and favor chronic oligoclonal 
activation over the focused selection of high-affinity antibodies 
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with effective potency against the pathogen. Davtyan et  al. 
compared levels of HCV core-specific antibodies expressing the 
1F7 idiotype in HCV-exposed individuals who either cleared 
infection or progressed to chronic infection. Levels of 1F7 idi-
otype expression were significantly higher on anti-HCV core 
antibodies from HCV-exposed individuals who progressed to 
chronic infection than on the anti-HCV core antibodies of those 
who spontaneously cleared HCV infection (30). In addition, a 
hierarchy of 1F7 idiotype expression levels was discernable in 
total circulating IgG and IgM with chronic infection greater 
than spontaneous clearance greater than HCV non-exposed 
individuals (30). The concept that pathogens establishing chronic 
infection, despite strong humoral responses, have evolved to 
select antibodies along a common idiotypic axis of the immune 
network represented by the 1F7 idiotype may also relate to previ-
ous studies of a public idiotype termed 16/6. Elevated levels of 
the 16/6 idiotype occur in autoimmune disease and microbial 
infection, while injection of mice with antibodies bearing the 
16/6 idiotype induces chronic immune activation and systemic 
lupus erythematosus (SLE)-like symptoms (35–38). In this case, 
there also appears to be a link between induction of antibodies 
along a common idiotypic axis demarcated by the 16/6 idiotype, 
immune activation, and autoreactivity. Based on these studies, 
the concept of pathogenic idiotypes arose, where idiotypes such 
as 16/6 identify antibodies that are directly autoreactive or have 
the capacity to disturb idiotypic regulation in ways that promote 
chronic activation and development of autoimmunity (39, 40). 
Identification of the distinct B1 B cell subset as the primary source 
of neonatal and natural antibodies with both a high frequency 
of autoreactivity and high connectivity apparently separated the 
B cell repertoire into subdivisions engaged in developmental 
regulation versus protection against pathogens. Although B1 B 
cells are distinguished by their developmental pathway, T cell 
independence and scarcity of somatic hypermutation or isotype 
switching, their use of the same set of germ-line antigen receptor 
genes as B2 B cells guarantees some level of idiotypic overlap 
between the two repertoires.
The fraction of CD5-expressing (B1) and CD5-negative B cells 
carrying the 1F7 idiotype was measured in uninfected controls 
and individuals with chronic HCV infection by flow cytometry. 
While there was expansion of 1F7-expressing B cells in both sub-
sets in chronic HCV infection, it was clearly skewed toward the 
CD5-expressing subset with up to 30% of B1 B cells expressing 
the 1F7 Id in some HCV-infected individuals compared to <2% 
in uninfected controls (30). Despite this marked effect of HCV 
infection on expansion of B1 B cells expressing the 1F7 idiotype, 
the majority of circulating antibodies against HCV and HIV-1 
that express the 1F7 idiotype have undergone secondary receptor 
modification and, therefore, appear to originate from the B2 B cell 
subset (17, 18, 22, 23, 29).
ANTi-Hiv-1 ANTiBODY BReADTH wiTHiN 
THe 1F7 iDiOTYPe
Engagement of both the B1 and B2 subsets in response 
to an infection is unusual with respect to their perceived 
independent roles, different interactions with T cells, level of 
connectivity, and frequency of autoreactivity. Chronic infec-
tion allows for the investigation of the long-term influence that 
selective expression of a common idiotype has on evolution 
of antibodies against an infectious agent. Despite demonstra-
tions of anti-HIV-1 antibodies against different proteins and 
across numerous HIV-1-infected donors carrying the 1F7 
idiotype; until recently, little attention was paid to the breadth 
of these idiotypic antibodies (17, 18). An ideal starting point 
for assessing the breadth of 1F7-idiotypic antibodies is to 
screen anti-HIV-1 BnAbs for expression of the idiotype as the 
process of antibody evolution within a common idiotypic space 
is intricately illustrated in the development of BnAbs against 
HIV-1. Anti-HIV-1 BnAbs are a subset of antibodies capable 
of neutralizing wide arrays of HIV-1 isolates, both within and 
across viral subtypes (41). These antibodies have great poten-
tial as prophylactics against HIV-1, as upon passive transfer or 
gene delivery to macaques and humanized mice they provide 
protection from challenges with SHIV and HIV-1, respectively 
(42–46). Approximately 20% of HIV-1-infected individuals 
develop antibodies with broadly neutralizing activity against 
different HIV viruses (47). The HIV-1 BnAbs are unique in 
that the variable regions have undergone extensive levels of 
somatic hypermutation not replicated using currently available 
vaccine formulations (48). Germ-line precursors of the HIV-1 
BnAb generally bind HIV-1 envelope glycoproteins poorly, if 
at all (49). As such, selection of such antibodies may initially 
require non-HIV-1 antigens (50). Fine-tuning the anti-HIV-1 
specificity of these antibodies, as well as the generation of 
broad neutralization capacity, would likely require additional 
rounds of selection and somatic hypermutation. To assess the 
breadth of 1F7-idiotypic antibodies, Parsons et  al. screened 
six well-characterized HIV-1 BnAbs (i.e., 2G12, b12, VRC01, 
2F5, 4E10, and Z13e1) for expression of the 1F7 idiotype via 
ELISA, and demonstrated the presence of the 1F7 idiotype on 
all six antibodies (51). Given that 1F7-idiotypic antibodies 
are observed within a majority of HIV-1-infected individuals, 
but BnAbs are only detected in approximately 20% of infected 
individuals, this observation raised questions about how 
BnAbs develop from antibodies within the relatively common 
1F7-idiotypic node.
Previous studies demonstrated that anti-HIV-1 antibody 
responses are subject to a form of original antigenic sin, 
known as repertoire freeze and deceptive imprinting (32, 52, 
53). Establishment of antibodies against the contemporane-
ous autologous virus initiates this phenomenon during acute 
infection. Although the virus rapidly escapes to evade the 
abilities of these antibodies to suppress viral replication, B-cells 
carrying B-cell receptors (BCR) corresponding to these anti-
bodies sufficiently recognize the escaped virus to be selected 
to undergo further rounds of somatic hypermutation (or at 
least keep responding to subsequent antigenic challenges). 
The continuous reselection of these early-established B-cell 
responses sustains the early-induced antibody response at the 
expense of novel B-cell responses more specific for the contem-
poraneous autologous viruses of chronic infection. Evidence of 
this phenomenon includes maintenance of skewed κ/λ ratios 
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throughout infection, restricted and biased variable region 
gene usage throughout infection and persistence of antibody 
clones recognizing earlier viral variants, despite escape many 
months prior (54–57). Given the occurrence of repertoire freeze 
during HIV-1 infection, Parsons et al. hypothesized that BnAbs 
develop from 1F7-idiotypic antibodies established during early 
infection through multiple rounds of selection and somatic 
hypermutation (51). To assess this possibility, they screened 
serial plasma samples from six HIV-infected donors over time 
points ranging from acute through chronic infection to deter-
mine if 1F7-idiotypic antibodies arise during acute infection 
and are sustained throughout infection. Indeed, 1F7-idiotypic 
antibodies were detected in plasma samples collected within the 
first 3  months of HIV-1 infection, and these antibodies were 
expanded and sustained with longer duration of infection. This 
observation suggests that 1F7-idiotypic antibodies engaged 
during acute infection and sustained throughout infection in 
an idiotypic repertoire freeze are driven through repeated selec-
tion and somatic hypermutation to develop into BnAbs. This 
putative route to BnAb development is consistent with pathways 
hypothesized by others and has implications for designing 
BnAb-inducing vaccines.
Consistent with the hypothesis that BnAbs develop through 
repeated selection and somatic hypermutation of 1F7-idiotypic 
antibodies induced early in infection, Liao et al. recently dem-
onstrated directly that antibodies capable of neutralizing a broad 
range of HIV-1 isolates develop as a result of repeated selection 
and mutation of antibodies by constantly evolving autologous 
HIV-1 (58). Haynes et  al. hypothesized that BnAbs might be 
inducible through vaccination strategies that sequentially expose 
vaccine recipients to HIV-1 envelope antigens selected on the 
basis of binding to chronologically relevant antibody isolates, 
derived from HIV-1-infected donors that developed BnAbs (59). 
This vaccination strategy might benefit from inclusion of a prime 
and/or boost with F(ab)2 of the murine monoclonal anti-idiotypic 
antibody used to detect the 1F7 idiotype in in vitro assays. As 
anti-HIV-1 BnAbs appear to be selected from the 1F7-idiotypic 
repertoire, a prime with the anti-1F7 F(ab)2 should focus the 
B-cell response of later immunizations with relevant HIV-1 
envelope antigens within the relevant B-cell repertoire. Similarly, 
boosts with anti-1F7 F(ab)2 might have the benefit of increasing 
the frequency of the relevant B-cell responses induced by the 
sequential vaccination strategy.
In addition to the ability of BnAb to prevent HIV-1 infec-
tion, non-neutralizing anti-HIV-1 antibodies have also recently 
gained attention as potentially protective moieties. Indeed, the 
ability of non-neutralizing antibodies to mediate antibody-
dependent cellular cytotoxicity (ADCC) against HIV-1 was 
linked to the partial success of the RV144 Thai vaccine trial 
(60–62). Similarly, the ability of antibodies to mediate ADCC 
has been linked to protection against infection with pathogenic 
SIV challenge in macaques immunized with live-attenuated SIV 
(63). The ADCC competency of antibodies passively transferred 
via breast milk from HIV-1-infected mothers to their children 
was also associated with a lower likelihood of mother-to-child 
transmission (64). The breadth of these non-neutralizing ADCC 
competent antibodies, defined as the ability of such antibodies 
to trigger ADCC against target cells expressing HIV-1 envelope 
antigens from different viral subtypes, appears important to 
their protective capacity. In fact, a recent assessment of the 
breadth of ADCC antibodies from HIV-1-infected controllers 
and progressors demonstrated more breadth in controllers 
(65). Therefore, it is likely imperative to understand the origin 
of HIV-1 envelope binding antibodies with broad recogni-
tion profiles. In this regard, Parsons et  al. recently assessed 
expression of the 1F7 idiotype on broadly reactive anti-HIV-1 
antibodies from individuals infected with HIV-1 subtype B that 
cross-reacted with HIV-1 envelopes (i.e., gp140) from subtype B, 
A, and AE viral isolates (66). The 1F7 idiotype was detected on 
antibodies binding to each HIV-1 subtype envelope, suggesting 
broad recognition within the anti-HIV-1 1F7-idiotypic node. 
Similarly, when expression of the 1F7 idiotype was assessed on 
subtype B envelope (i.e., gp120)-binding anti-HIV-1 antibodies 
derived from individuals infected with non-subtype B viruses, 
the idiotype was observed on antibodies from 15/19 donors. 
Together with data regarding 1F7-idiotypic expression on anti-
HIV-1 BnAbs, the expression profile of the 1F7 idiotype on anti-
HIV-1-binding antibodies with broad recognition capabilities 
suggests that vaccines focusing anti-HIV-1 antibody responses 
within the 1F7-idiotypic repertoire can achieve a substantial 
breadth of HIV-1 recognition.
How best to exploit the immense breadth available within the 
1F7-idiotype domain remains an open question. The potential 
breadth of this node may be dramatically narrowed by repertoire 
freezes induced by HIV-1 infection itself or by vaccination with 
single strains. Recently, Kohler discussed that the establishment 
of such repertoire freezes results in “back-boosts” upon exposure 
to antigenically related, yet distinct, antigens, as would be the case 
upon challenge with a different viral strain than that utilized for 
vaccination (67). He further proposed utilizing the full breadth 
of the 1F7-idiotypic repertoire by “forward-boosting” or priming 
the entire 1F7 repertoire prior to exposure to any HIV-1 antigens. 
Future research should evaluate the ability of such a “forward-
boosting” protocol to establish broadly reactive anti-HIV-1 
antibodies capable of mediating potent effector functions against 
HIV-1 or HIV-1 infected cells (see Figure 1 depicting the forward 
boosting strategy).
SUMMARY
The concept and significance of dominant idiotypes surfaced 
more than 40  years ago, and the practical value of internal 
image antibodies or network antigens as immunogens was 
realized shortly afterwards. Regulatory idiotypes, the levels of 
which might reflect immune trajectories toward autoimmunity 
or immune deficiency, were proposed in the mid 1980s and 
continue to be studied today in autoimmunity, cancer, and 
infectious disease. In this review, we described how antibod-
ies against multiple antigens of retroviruses capable of causing 
immune deficiency syndromes, including HIV-1, SIV, and SHIV, 
and also antibodies against HCV share a common idiotype 
designated 1F7. Expression of this idiotype is associated with a 
FiGURe 1 | Overcoming deceptive imprinting through forward boosting. The left side of the diagram represents the B cell response to HIV-1 upon natural 
exposure to HIV-1 or immunization with an HIV-1 vaccine construct. This exposure results in a subset of naive B cell clones (N), which carry B cell receptors capable 
of binding HIV-1 antigens, being selected to undergo differentiation into memory B cells (M). This initial selection process induces a phenomenon known as 
deceptive imprinting. This phenomenon results in a reselection of previously selected B cell clones, at the expense of naive B cells carrying novel antigen-binding B 
cell receptor specificities, upon exposure to mutated HIV-1 or alternative HIV-1 vaccine constructs. The right side of the diagram depicts the forward-boosting 
strategy. This strategy predicts priming 1F7-idiotypic B cell clones (i.e., those expressing orange tipped B cell receptors), which exhibit broad HIV-1 reactivity, will 
establish a larger repertoire of B cell clones that can contribute to the anti-HIV-1 antibody response following future exposure or immunization. Upon future exposure 
to HIV-1 or an HIV-1 vaccine construct boosting of a subset of the memory B cells established from the initial anti-1F7-idiotype prime will be observed. Additional 
anti-1F7-idiotype primed clones should be boosted, and not impeded by deceptive imprinting, upon exposure to cognate antigens on mutated HIV-1 or alternative 
HIV-1 vaccine constructs. The bottom of the diagram, on both the left and right sides, demonstrates that selected B cell clones contribute to the antibody response 
upon becoming long-lived plasma cells (P).
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form of clonal dominance that appears to restrict development 
of neutralizing antibodies against contemporaneous infecting 
strains of HIV-1 and imposes a trajectory toward chronic infec-
tion with HCV. However, BnAbs that develop against HIV-1 
do bear the 1F7 idiotype, indicating that the same idiotypic 
axis accommodating clonal dominance and original antigenic 
sin also accommodates antibody evolution toward the highly 
mutated progeny capable of neutralizing diverse strains of HIV-
1. Learning how to exploit this axis selectively to prime for the 
development of BnAbs in advance of viral exposure may be a 
key to more effective vaccination against chronic viruses, such 
as HIV-1, HCV, and others.
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